Kirsty (Insulin Aspart)

Insulin Aspart is a rapid‑acting insulin used to manage blood glucose in diabetes mellitus.

• Type 1 diabetes mellitus: provides mealtime glucose control and reduces post‑prandial hyperglycemia.
• Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve target glycemic levels.
• Insulin pump therapy: serves as a rapid‑acting bolus insulin for continuous subcutaneous insulin infusion devices.

• Insulin Aspart binds to the insulin receptor on target cells, activating the receptor’s intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote glucose uptake in muscle and adipose tissue, suppress hepatic glucose production, and facilitate glycogen synthesis, resulting in rapid reduction of blood glucose after meals.

Insulin Aspart may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypoglycemia: low blood glucose levels, the most frequent reaction.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increase in body weight associated with insulin therapy.
• Nausea: feeling of sickness or upset stomach.
• Headache: mild to moderate head pain.

Serious or Rare Side Effects

• Severe hypoglycemia: neurological symptoms requiring immediate assistance.
• Allergic reactions: rash, urticaria, or anaphylaxis in rare cases.
• Lipohypertrophy: abnormal fat accumulation at injection sites.
• Serum insulin antibodies: may alter insulin action.

When using Insulin Aspart, several precautions should be observed to ensure safe and effective therapy.

• Dose adjustment: tailor the dose to carbohydrate intake, blood glucose readings, and physical activity.
• Renal impairment: monitor glucose closely and consider dose reduction.
• Hepatic impairment: use with caution and observe for altered insulin clearance.
• Pregnancy and lactation: only use if benefits outweigh potential risks.
• Hypoglycemia risk: educate patients on recognizing and treating low blood glucose.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with other medicines, affecting glucose control or increasing adverse event risk.

Major Interactions (Avoid)

• Beta‑blockers: may mask symptoms of hypoglycemia.
• Monoamine oxidase inhibitors: can potentiate insulin’s glucose‑lowering effect.
• Glucagon: concurrent use may lead to unpredictable glucose responses.

Moderate Interactions (Monitor Closely)

• Thiazolidinediones: increased risk of fluid retention and edema.
• Diuretics: may influence potassium balance and affect insulin action.
• Oral contraceptives: may alter insulin requirements and glucose control.